Welcome, New Members!

Jun 26, 2017

Aprea Therapeutics           

Aprea Therapeutics is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53. The Company’s lead program, APR-246, a first-in-class small molecule drug candidate, is in Phase Ib/II clinical development in ovarian cancer patients, and additional clinical studies with APR-246 in other cancer indications are planned. In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap, acting as local lead investor, and existing investor, Karolinska Development.

Prospective Research

Prospective Research, Inc. was founded with a vision to develop novel, lifesaving antibiotics. 70% of todays antibiotics come from soil microbes and yet less than 10% of the microbe's potential has been tapped. Microbes have typically been cultured in isolation, removing them from the stimuli they need to produce their most potent antibiotics.  Our MicrobeMiner™ platform mimics stimuli in the soil, giving us exclusive access to untapped antibiotics.


Save time and money using our in silico methods to identify the molecules that matter to your project.

Discover, design and optimize the best small molecules with:

  • Unrivalled insight into your protein-ligand systems
  • Outstanding visualization and multi-parameter optimization tools
  • Biologically relevant searches of millions of compounds.

Chemists from the world’s leading research organizations trust us to help them understand the key chemical interactions that underpin biological activity.  We provide software and services to 8 out of the top 10 pharmaceutical companies.

Use our software in-house or engage our scientists to work alongside your research team.

Donnelley Financial Solutions

Donnelley Financial Solutions (NYSE: DFIN) provides software and services that enable clients to communicate with confidence in a complex regulatory environment. With 3,500 employees in 61 locations across 18 countries, we provide thousands of clients globally with innovative tools for content creation, management and distribution, as well as data analytics and multi-lingual translations services. Leveraging advanced technology, deep-domain expertise and 24/7 support, we deliver cost-effective solutions to meet the evolving needs of our clients.

Primecore Program Management

Primecore is a consultancy company that supports Biotech and Gene Therapy clients with the development and delivery of their operations strategy in order to meet the future needs of their product portfolio. Primecore is a world leader in the areas of; Operations Strategy Development, Strategic Portfolio Management, Program Management and Capital Project Management.


Synlife is an R&D biotech company exploring the potential of cell-free synthetic biology.


Founded in 2009 and located in Wädenswil at the lake of Zurich, Switzerland, Creoptix AG is a private company specialized in optical instruments and consumables for the label-free analysis of molecular interactions at best-in-class sensitivity for life science research and the drug discovery industry.

We're also excited to welcome four MassCONNECT graduates to MassBio:

  • Fairbanks Pharmaceuticals 
  • Obsidio Medical 
  • Genma Biosciences
  • Versatope

See all MassBio News